» Articles » PMID: 29479819

Prognostic Factors in Breast Phyllodes Tumors: a Nomogram Based on a Retrospective Cohort Study of 404 Patients

Overview
Journal Cancer Med
Specialty Oncology
Date 2018 Feb 27
PMID 29479819
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to explore the independent prognostic factors related to postoperative recurrence-free survival (RFS) in patients with breast phyllodes tumors (PTBs). A retrospective analysis was conducted in Fudan University Shanghai Cancer Center. According to histological type, patients with benign PTBs were classified as a low-risk group, while borderline and malignant PTBs were classified as a high-risk group. The Cox regression model was adopted to identify factors affecting postoperative RFS in the two groups, and a nomogram was generated to predict recurrence-free survival at 1, 3, and 5 years. Among the 404 patients, 168 (41.6%) patients had benign PTB, 184 (45.5%) had borderline PTB, and 52 (12.9%) had malignant PTB. Fifty-five patients experienced postoperative local recurrence, including six benign cases, 26 borderline cases, and 22 malignant cases; the three histological types of PTB had local recurrence rates of 3.6%, 14.1%, and 42.3%, respectively. Stromal cell atypia was an independent prognostic factor for RFS in the low-risk group, while the surgical approach and tumor border were independent prognostic factors for RFS in the high-risk group, and patients receiving simple excision with an infiltrative tumor border had a higher recurrence rate. A nomogram developed based on clinicopathologic features and surgical approaches could predict recurrence-free survival at 1, 3, and 5 years. For high-risk patients, this predictive nomogram based on tumor border, tumor residue, mitotic activity, degree of stromal cell hyperplasia, and atypia can be applied for patient counseling and clinical management. The efficacy of adjuvant radiotherapy remains uncertain.

Citing Articles

Borderline Phyllodes Breast Tumors: A Comprehensive Review of Recurrence, Histopathological Characteristics, and Treatment Modalities.

Borella F, Porpiglia M, Gallio N, Cito C, Boriglione L, Capella G Curr Oncol. 2025; 32(2).

PMID: 39996866 PMC: 11854776. DOI: 10.3390/curroncol32020066.


Margin Width and Local Recurrence in Patients with Phyllodes Tumors of the Breast.

Del Calvo H, Wu Y, Lin H, Nassif E, Zarzour M, Guadagnolo B Ann Surg Oncol. 2024; 31(12):8048-8056.

PMID: 39085546 DOI: 10.1245/s10434-024-15892-8.


NKILA is a novel suppressor of local recurrence in women breast malignant phyllodes tumor patients via inhibition of the NF-κB pathway.

Mi Y, Yan L, Jin H, Jin M, Zhu D, Huang H Heliyon. 2024; 10(13):e33259.

PMID: 39027510 PMC: 11255658. DOI: 10.1016/j.heliyon.2024.e33259.


LncRNA ZFPM2-AS1 promotes phyllodes tumor progression by binding to CDC42 and inhibiting STAT1 activation.

He S, Huang G, Lei R, Jia R, He Z, Chen J Acta Pharm Sin B. 2024; 14(7):2942-2958.

PMID: 39027255 PMC: 11252458. DOI: 10.1016/j.apsb.2024.04.023.


Expression of amine oxidase-related proteins in breast phyllodes tumor.

Kim H, Koo J Histol Histopathol. 2024; 40(1):39-47.

PMID: 38887035 DOI: 10.14670/HH-18-773.


References
1.
Zhou Z, Wang C, Sun X, Yang Z, Yu X, Guo X . Diagnostic performance of core needle biopsy in identifying breast phyllodes tumors. J Thorac Dis. 2017; 8(11):3139-3151. PMC: 5179415. DOI: 10.21037/jtd.2016.10.109. View

2.
Morales-Vasquez F, Gonzalez-Angulo A, Broglio K, Lopez-Basave H, Gallardo D, Hortobagyi G . Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. Breast J. 2007; 13(6):551-6. DOI: 10.1111/j.1524-4741.2007.00510.x. View

3.
Fajdic J, Gotovac N, Hrgovic Z, Kristek J, Horvat V, Kaufmann M . Phyllodes tumors of the breast diagnostic and therapeutic dilemmas. Onkologie. 2007; 30(3):113-8. DOI: 10.1159/000099580. View

4.
Macdonald O, Lee C, Tward J, Chappel C, Gaffney D . Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006; 107(9):2127-33. DOI: 10.1002/cncr.22228. View

5.
Barrio A, Clark B, Goldberg J, Hoque L, Bernik S, Flynn L . Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Ann Surg Oncol. 2007; 14(10):2961-70. DOI: 10.1245/s10434-007-9439-z. View